Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
Gründer, G
Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. [electronic resource] - Pharmacopsychiatry Feb 2006 - S21-5 p. digital
Publication Type: Journal Article
0176-3679
10.1055/s-2006-931485 doi
Antipsychotic Agents--adverse effects
Aripiprazole
Cerebral Cortex--drug effects
Corpus Striatum--drug effects
Dopamine Agonists--adverse effects
Humans
Limbic System--drug effects
Mesencephalon--drug effects
Neural Pathways--drug effects
Piperazines--adverse effects
Quinolones--adverse effects
Receptors, Dopamine D2--agonists
Schizophrenia--diagnosis
Schizophrenic Psychology
Serotonin 5-HT2 Receptor Antagonists
Treatment Outcome
Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. [electronic resource] - Pharmacopsychiatry Feb 2006 - S21-5 p. digital
Publication Type: Journal Article
0176-3679
10.1055/s-2006-931485 doi
Antipsychotic Agents--adverse effects
Aripiprazole
Cerebral Cortex--drug effects
Corpus Striatum--drug effects
Dopamine Agonists--adverse effects
Humans
Limbic System--drug effects
Mesencephalon--drug effects
Neural Pathways--drug effects
Piperazines--adverse effects
Quinolones--adverse effects
Receptors, Dopamine D2--agonists
Schizophrenia--diagnosis
Schizophrenic Psychology
Serotonin 5-HT2 Receptor Antagonists
Treatment Outcome